Market Overview

NeoGenomics Launches New Test for Detection of Mutations in Calreticulin Gene

NeoGenomics (NASDAQ: NEO) announced today that it has validated and launched a new test for the detection of mutations in the calreticulin (CALR) gene.  The CALR gene is a novel biomarker that was reported to be specific for myeloproliferative neoplasms (MPN) for the first time at the annual meeting of the American Society of Hematology (ASH) last month.  Since then, findings on the CALR gene have been published in the three articles referenced below.

See full press release

Posted-In: News Guidance Management Global

 

Most Popular

Related Articles (NEO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters